Abstract
Ovarian cancer is the fifth most common cancer affecting women and at present, stands as the most lethal gynecologic malignancy. The poor disease outcome is due to the nonspecific symptoms and the lack of effective treatment at advanced stages. Thus, it is of utmost importance to understand ovarian carcinoma through several lenses and to dissect the role that the unique peritoneal tumor microenvironment plays in ovarian cancer progression and metastasis. This review seeks to highlight several determinants of this unique tumor microenvironment, their influence on disease outcome and ongoing clinical trials targeting these determinants.
| Original language | English |
|---|---|
| Pages (from-to) | 5047-5056 |
| Number of pages | 10 |
| Journal | Cancer medicine |
| Volume | 7 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2018 |
Keywords
- Antineoplastic Agents/pharmacology
- Clinical Trials as Topic
- Disease Progression
- Female
- Humans
- Ovarian Neoplasms/drug therapy
- Tumor Microenvironment/drug effects
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS